Literature DB >> 9187109

A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells.

M Mathiak1, C Yenisey, D S Grant, B Sharma, R V Iozzo.   

Abstract

Perlecan is a major heparan sulfate proteoglycan of basement membranes and cell surfaces. Because of its strategic location and ability to store and protect growth factors, perlecan has been implicated in the control of tumor cell growth and metastatic behavior. To test the role of perlecan in malignancy, we generated several stably transfected clones of HT-1080, a human fibrosarcoma cell line, harboring a perlecan cDNA in the antisense orientation. Surprisingly, clones with a reduced synthesis of perlecan mRNA and protein core grew faster, formed larger colonies in semisolid agar, and induced faster formation of s.c. tumors in nude mice than the wild-type cells. Their growth properties in vitro were independent of exogenous basic fibroblast growth factor. Reduction of perlecan expression was associated with three distinct properties typical of tumor cells with a more aggressive phenotype: enhanced migration through 8-microm-pore filter, increased invasion in Matrigel-coated filters, and heightened adhesiveness to type IV collagen substrata. These results thus provide the first evidence that perlecan may inhibit the growth and invasiveness of fibrosarcoma cells in a basic fibroblast growth factor-independent pathway and raise the possibility that perlecan may prevent the infiltration of host tissues in mesenchymal neoplasms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187109

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.

Authors:  R V Iozzo; J D San Antonio
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Tumor attenuation by combined heparan sulfate and polyamine depletion.

Authors:  Mattias Belting; Lubor Borsig; Mark M Fuster; Jillian R Brown; Lo Persson; Lars-Ake Fransson; Jeffrey D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 3.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 4.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

Review 5.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

6.  Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan.

Authors:  C Marchisone; F Del Grosso; L Masiello; M Prat; L Santi; D M Noonan
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

7.  Endorepellin-evoked Autophagy Contributes to Angiostasis.

Authors:  Atul Goyal; Maria A Gubbiotti; Daphney R Chery; Lin Han; Renato V Iozzo
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

Review 8.  Diverse cell signaling events modulated by perlecan.

Authors:  John M Whitelock; James Melrose; Renato V Iozzo
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

Review 9.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

10.  Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells.

Authors:  Chris D Willis; Chiara Poluzzi; Maurizio Mongiat; Renato V Iozzo
Journal:  FEBS J       Date:  2013-02-28       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.